Cancer Immunotherapy: Emerging Topics and Future Perspectives: This article aims to present major types of cancer immunotherapy, how they are applied, and the future perspectives of this field.
Author: 
Tingting XuAuthors Info & Claims
Pages 122 - 128
Abstract
For years, cancer has been one of the most serious diseases that account for an extremely high percentage of death rate. Initially, people used chemotherapy, radiation therapy, hormonal therapy, targeted therapy, and palliative care to treat cancer. However, it was almost impossible to assure patients can live cancer-free for the rest of their life. Fortunately, with the development of immunotherapy, there have been more and more cancer patients recover from cancer successfully, which never come back within their lifetime. In this article, we talked about the major types of cancer immunotherapy, how they are applied, and the future perspectives of this field.
References
[1]
Rebecca L Siegel, Kimberly D Miller, and Ahmedin Jemal. 2017. Cancer Statistics, 2017. CA Cancer J Clin 67, 1 (January 2017), 7-30. https://doi.org/ 10.3322/caac.21387
[2]
Max Roser and Hannah Ritchie. 2015. Cancer. Retrieved January 26, 2021 from https://ourworldindata.org/cancer
[3]
Mallmann P and Krebs D. 1995. Gewinnung und Aktivierung tumorinfiltrierender Lymphozyten (TIL) im Rahmen einer Lymphokinaktivierten Killerzelltherapie (LAK-TIL-Therapie) bei Patientinnen mit fortgeschrittenen Mamma- und Ovarialkarzinom [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma]. Gynakol Geburtshilfliche Rundsch 35 suppl 1 (1999), 161-165. https://doi.org/10.1159/000272590
[4]
Stephanie L. Goff, Franz O. Smith, Jacob A. Klapper, Richard Sherry, John R. Wunderlich, Seth M. Steinberg, Donald White, Steven A. Rosenberg, Mark E. Dudley, and James C. Yang. 2010. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 33, 8 (October 2010), 840-847. https://doi.org/10.1097/CJI.0b013e3181f05b91
[5]
Joost H van den Berg, Bianca Heemskerk, Nienke van Rooij, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Annelies Jorritsma-Smit, Marit M van Buuren, Pia Kvistborg, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Michel W J M Wouters, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher and John B A G Haanen. 2020. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer 8, 2 (August 2020), e000848. https://doi.org/10.1136/jitc-2020-000848
[6]
Marie-Andrée Forget, Cara Haymaker, Kenneth R Hess, Yuzhong Jeff Meng, Caitlin Creasy, Tatiana Karpinets, Orenthial J Fulbright, Jason Roszik, Scott E Woodman, Young Uk Kim, Donastas Sakellariou-Thompson, Ankit Bhatta, Arely Wahl, Esteban Flores, Shawne T Thorsen, René J Tavera, Renjith Ramachandran, Audrey M Gonzalez, Christopher L Toth, Seth Wardell, Rahmatu Mansaray, Vruti Patel, Destiny Joy Carpio, Carol Vaughn, Chantell M Farinas, Portia G Velasquez, Wen-Jen Hwu, Sapna P Patel, Michael A Davies, Adi Diab, Isabella C Glitza, Hussein Tawbi, Michael K Wong, Suzanne Cain, Merrick I Ross, Jeffrey E Lee, Jeffrey E Gershenwald, Anthony Lucci, Richard Royal, Janice N Cormier, Jennifer A Wargo, Laszlo G Radvanyi, Carlos A Torres-Cabala, Rameen Beroukhim, Patrick Hwu, Rodabe N Amaria, and Chantale Bernatchez. 2018. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24, 18 (September 2018), 4416-4428. https://doi.org/10.1158/1078-0432.CCR-17-3649
[7]
Xiang Zhou, Junlong Wu, Chunguang Duan, and Yingjie Liu. 2020. Retrospective analysis of adoptive TIL therapy plus anti-PD1 therapy in patients with chemotherapy-resistant metastatic osteosarcoma. J Immunol Res 2020 (October 2020), 7890985. https://doi.org/10.1155/2020/7890985
[8]
Y Niitsu, N Watanabe, H Kondo, and Y Kanisawa. 1990. [Receptor-mediated cancer therapy–tumoricidal cytokines, adoptive therapy of LAK, TIL]. Gan To Kagaku Ryoho 17, 6 (June 1990), 1134-1141. https:// .ncbi.nlm.nih.gov/1693487/
[9]
Richard A Morgan, Mark E Dudley, John R Wunderlich, Marybeth S Hughes, James C Yang, Richard M Sherry, Richard E Royal, Suzanne L Topalian, Udai S Kammula, Nicholas P Restifo, Zhili Zheng, Azam Nahvi, Christiaan R de Vries, Linda J Rogers-Freezer, Sharon A Mavroukakis, and Steven A Rosenberg. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 5796 (October 2006), 126-129. https://doi.org/10.1126/science.1129003
[10]
Paul F Robbins, Sadik H Kassim, Thai L N Tran, Jessica S Crystal, Richard A Morgan, Steven A Feldman, James C Yang, Mark E Dudley, John R Wunderlich, Richard M Sherry, Udai S Kammula, Marybeth S Hughes, Nicholas P Restifo, Mark Raffeld, Chyi-Chia R Lee, Yong F Li, Mona El-Gamil, and Steven A Rosenberg. 2015. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21, 5 (March 2015), 1019-1027. https://doi.org/10.1158/1078-0432.CCR-14-2708
[11]
Isabella Monia Montagner, Alessandro Penna, Giulio Fracasso, Debora Carpanese, Anna Dalla Pietà, Vito Barbieri, Gaia Zuccolotto, and Antonio Rosato. 2020. Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells 9, 6 (June 2020), 1382. https://doi.org/10.3390/cells9061382
[12]
Nicholas A P S Buss, Simon J Henderson, Mary McFarlane, Jacintha M Shenton, and Lolke de Haan. 2012. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12, 5 (October 2012), 615-622. https://doi.org/ 10.1016/j.coph.2012.08.001
[13]
Nuventra 2018. Monoclonal antibodies: past, present, and future. Retrieved January 26, 2021 from https://www.nuventra.com/resources/blog/monoclonal-antibodies-past-present-and-future/
- Cancer Immunotherapy: Emerging Topics and Future Perspectives: This article aims to present major types of cancer immunotherapy, how they are applied, and the future perspectives of this field.
Recommendations
Overview of Cancer Immunotherapy
ICBBE '20: Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics EngineeringCancer is known as malignant tumor, with a high fatality rate. Early treatment include resection, radiation therapy and chemotherapy, however, due to the severe injure to human, immunotherapy has been proposed. Immune checkpoints are one of the major ...
Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines
AbstractAdvancements in cancer immunotherapy have shown significant outcomes in treating cancers. To design effective immunotherapy, it's important to understand immune response of a patient based on its genomic profile. However, analyses to do that ...
Highlights- CancerHLA-I stores information of HLA-alleles, cancer-specific peptides and cytokines expression of cancer patients.
- Correlation and survival analysis were performed using 8346 cancer patients for twenty cancer types.
- CancerHLA-I ...
Investigating Conventional and Novel Methods for Treatment of Cancer
ICBBB '23: Proceedings of the 2023 13th International Conference on Bioscience, Biochemistry and BioinformaticsCancer is one of the most challenging health problems facing humankind. Conventional treatments such as surgery, chemotherapy and radiotherapy can usually have a positive patient outcome in the early-stage tumours without metastasis. However, late-stage ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
May 2021
347 pages
ISBN:9781450389846
DOI:10.1145/3472813
Copyright © 2021 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected].
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 26 October 2021
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ICMHI 2021
ICMHI 2021: 2021 5th International Conference on Medical and Health Informatics
May 14 - 16, 2021
Kyoto, Japan
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 237Total Downloads
- Downloads (Last 12 months)88
- Downloads (Last 6 weeks)15
Reflects downloads up to 30 Nov 2024
Other Metrics
Citations
View Options
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML FormatLogin options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign in